<DOC>
	<DOCNO>NCT00580060</DOCNO>
	<brief_summary>This pilot trial investigate use GM-CSF DNA adjuvant peptide vaccination patient metastatic melanoma . The objective study determine safety adjuvant effect vaccination gene cod human GM-CSF multi-epitope melanoma peptide vaccine ( tyrosinase gp100 peptide ) patient AJCC stage IIB , IIC , III IV melanoma HLA-A2+ . We assess whether use GM-CSF DNA safe generates immune response peptide derive antigen melanoma cell .</brief_summary>
	<brief_title>Injection Of AJCC Stage IIB , IIC , III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant : A Pilot Trial To Assess Safety And Immunity</brief_title>
	<detailed_description>This pilot trial investigate use GM-CSF DNA adjuvant peptide vaccination patient metastatic melanoma . The objective study determine safety adjuvant effect vaccination gene cod human GM-CSF multi-epitope melanoma peptide vaccine ( tyrosinase gp100 peptide ) patient AJCC stage IIB , IIC , III IV melanoma HLA-A2+ . We assess whether use GM-CSF DNA safe generates immune response peptide derive antigen melanoma cell . In Dose Ranging part study , cohorts 3 patient treat increase dose level GM-CSF DNA deliver subcutaneously ( 100 , 400 , 800 ug ) , follow administration peptide subcutaneously site day 5 day 6 . Patients treat monthly three immunization . Pharmacokinetic study perform first cycle . Patients ' peripheral blood mononuclear cell collect order measure T cell response induce vaccine . Toxicity assess part study , although expect achieve dose limit toxicity ( DLT ) . The dose second part study maximum tolerate dose . The second part study assess immunological efficacy vaccine . Nine patient receive GM-CSF DNA deliver subcutaneously one site , follow administration peptide site day 5 day 6 , every month three immunization . A total least 18 patient plan phase study . Patients ' peripheral blood mononuclear cell collect order measure T cell response induce vaccine . Specifically , Elispot assay CD8+ T cell responses peptide assess , primary method determine generation specific immune response peptide antigen .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients must document malignant melanoma , American Joint Commission Cancer ( AJCC ) stage IIB , IIC , III IV ( 54 ) . Patients resectable stage IIB , IIC III disease must undergo surgical resection participate study . Patients choroidal melanoma may participate fulfill one follow criterion : Basal diameter &gt; = 16 mm ; Height &gt; = 8 mm involvement ciliary body tumor . For patient , pathology slide must review Pathology Department Memorial SloanKettering Cancer Center confirmation melanoma diagnosis . Patients must HLAA2 positive . Patients must weigh least 25 kg eligible . Patients must able read consent form give inform consent . Parent legal guardian patient minor sign informed consent form . Patients must Karnofsky performance status least 80 . LDH ≤ 2x upper limit normal value ; albumin ≥ 3.5 mg/dl . Creatinine ≤ 2mg/dl AST ≤ 2 fold upper limit normal . A CBC prior vaccination WBC ≥ 3000 , platelets ≥ 100,000 . A negative serum bHCG within 2 week vaccination woman childbearing age . Patients must free detectable brain metastasis . ( Brain MRI CT preprotocol ) Patients may receive receive chemotherapy , immunotherapy radiation therapy within previous 4 week nitrosourea chemotherapy within previous 6 week . Patients must fully recover previous therapy surgery . Patients may previously immunize vaccine contain tyrosinase gp100 , peptides derived tyrosinase gp100 . Creatinine &gt; 2mg/dl ( history Creatinine &gt; 2 mg/dl ) AST ≥ 2 fold upper limit normal . Any medical condition use medication ( e.g. , active autoimmune disease , immunodeficiency corticosteroid ) might make difficult patient complete full course treatment respond immunologically vaccines ground exclusion , discretion Principal Investigator coPrincipal Investigators . Patients may take systemic corticosteroid ( orally intravenously ) within previous 6 week . Inhaled nasal steroid permit . Patients preexist retinal choroidal eye disease ( except outline section 5.1.1 ) exclude . Patients serious underlying medical condition , active infection require antimicrobial drug , active bleeding ineligible . Pregnant woman , woman le 3 month postpartum woman nurse eligible . Women childbearing age sexually active men must use appropriate contraception course study 3 month follow completion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>AJCC</keyword>
	<keyword>stage</keyword>
	<keyword>IIB</keyword>
	<keyword>IIC</keyword>
	<keyword>III</keyword>
	<keyword>IV</keyword>
	<keyword>Melanoma</keyword>
	<keyword>HLA-A2+</keyword>
	<keyword>Vaccine</keyword>
</DOC>